Shin D, Lee J, Kang E, Noh D, Cheun J, Lee J
JAMA Netw Open. 2024; 7(11):e2442663.
PMID: 39509133
PMC: 11544499.
DOI: 10.1001/jamanetworkopen.2024.42663.
Jiang Q, Liu X, Wu Y, DU J, Rao Y, Li J
Gland Surg. 2024; 13(6):927-941.
PMID: 39015697
PMC: 11247573.
DOI: 10.21037/gs-23-537.
Fofana S, Oraby T, Cobos E, Tripathi M
Res Sq. 2024; .
PMID: 38978582
PMC: 11230498.
DOI: 10.21203/rs.3.rs-4535192/v1.
Singh I, Gupta S, Deshmukh M, Gandhi M, Khopkar-Kale P
Cureus. 2024; 16(4):e58375.
PMID: 38756317
PMC: 11097618.
DOI: 10.7759/cureus.58375.
Sbaity E, Tamim H, Fuleihan G, Abbas J, Zahwe M, El Sayed R
BMC Cancer. 2024; 24(1):560.
PMID: 38704543
PMC: 11069273.
DOI: 10.1186/s12885-024-11910-w.
Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry.
Palmer S, Blomqvist C, Holmqvist M, Lindman H, Lambe M, Ahlgren J
BMC Cancer. 2024; 24(1):329.
PMID: 38468209
PMC: 10926626.
DOI: 10.1186/s12885-024-12073-4.
Evaluation Factors Affecting on Recurrence, Metastasis, and Survival of Breast Cancer in Iranian Women by Multi-State Model Approach.
Mousavi M, Hajizadeh E, Rasekhi A, Haghighat S
Iran J Public Health. 2023; 52(10):2186-2195.
PMID: 37899919
PMC: 10612554.
DOI: 10.18502/ijph.v52i10.13857.
The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages.
Sun S, Man X, Zhou D, Zheng F, Zhao J, Chen X
Cancer Med. 2023; 12(18):18850-18860.
PMID: 37688399
PMC: 10557883.
DOI: 10.1002/cam4.6509.
Does age affect outcome with breast cancer?.
Jackson E, Gondara L, Speers C, Diocee R, Nichol A, Lohrisch C
Breast. 2023; 70:25-31.
PMID: 37300985
PMC: 10382954.
DOI: 10.1016/j.breast.2023.06.001.
What Is Known about Breast Cancer in Young Women?.
Zhu J, Charkhchi P, Adekunte S, Akbari M
Cancers (Basel). 2023; 15(6).
PMID: 36980802
PMC: 10047861.
DOI: 10.3390/cancers15061917.
Updates on Lymphovascular Invasion in Breast Cancer.
Kuhn E, Gambini D, Despini L, Asnaghi D, Runza L, Ferrero S
Biomedicines. 2023; 11(3).
PMID: 36979946
PMC: 10046167.
DOI: 10.3390/biomedicines11030968.
Hypofractionated radiotherapy in young versus older women with breast cancer: a retrospective study from India.
Yadav B, Das D, Bansal A, Dahiya D
Rep Pract Oncol Radiother. 2022; 27(2):281-290.
PMID: 36299397
PMC: 9591044.
DOI: 10.5603/RPOR.a2022.0028.
The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
Verdial F, Mamtani A, Pawloski K, Sevilimedu V, DAlfonso T, Zhang H
Ann Surg Oncol. 2022; 29(6):3810-3819.
PMID: 35246810
PMC: 10901180.
DOI: 10.1245/s10434-022-11367-w.
Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age.
Takada K, Kashiwagi S, Asano Y, Goto W, Morisaki T, Shibutani M
World J Surg Oncol. 2022; 20(1):38.
PMID: 35177074
PMC: 8851811.
DOI: 10.1186/s12957-022-02513-5.
Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment.
Frundt T, Casar C, von Felden J, Scholer U, Priebe M, Kraczyk J
Cancers (Basel). 2022; 14(3).
PMID: 35159035
PMC: 8833746.
DOI: 10.3390/cancers14030768.
Trajectories of fear of cancer recurrence in young breast cancer survivors.
Schapira L, Zheng Y, Gelber S, Poorvu P, Ruddy K, Tamimi R
Cancer. 2021; 128(2):335-343.
PMID: 34614212
PMC: 9397577.
DOI: 10.1002/cncr.33921.
Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study.
Zhang W, Zhang B, He J, Fan J, Li J, Zhang B
Gland Surg. 2021; 10(1):175-185.
PMID: 33633974
PMC: 7882316.
DOI: 10.21037/gs-20-574.
Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.
Johnson H, Irish W, Vohra N, Wong J
Breast Cancer Res Treat. 2021; 187(3):805-814.
PMID: 33609208
DOI: 10.1007/s10549-021-06113-x.
Survival outcomes are associated with genomic instability in luminal breast cancers.
King L, Flaus A, Holian E, Golden A
PLoS One. 2021; 16(2):e0245042.
PMID: 33534788
PMC: 7857737.
DOI: 10.1371/journal.pone.0245042.
Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer.
Bastiaansen A, Timmermans A, Smid M, van Deurzen C, Hulsenboom E, Prager-van der Smissen W
Sci Rep. 2020; 10(1):22292.
PMID: 33339858
PMC: 7749122.
DOI: 10.1038/s41598-020-79248-4.